Home » Therapeutic Antibody » Antibody Engineering » Antibody Affinity Maturation

Antibody Affinity Maturation

5-100 fold Affinity Improvement

Affinity maturation is the process by which antibodies increased its affinity, avidity and activity through multiple rounds of somatic hyper mutation (SHM) in germinal centers. Successive generations of B cells mutate and present to the antigen, that recognize the antigen with high affinity will survive and the low affinity ones are eliminated. Affinity maturation process more often applied to antibody leads that are selected from library approaches using a phage display technique and the affinity of the leads have 10 –100 nM affinity levels to the target. In antibody drug discovery, affinity maturation is applied to antibody leads to increase the affinity at least 10 to 50 folds.

PML Library Based Affinity Maturation

GenScript ProBio provides affinity maturation service based on 2 methods. The first one is PML library based affinity maturation.

A PML (precise mutagenesis library) library is a site-saturation mutagenesis library or a saturation scanning mutagenesis library. Saturation mutations are performed on about 65 amino acids in all of the six CDR regions of the light and heavy chains. Each amino acid is mutated into the other 19 amino acids with the same distribution.

By screening a PML library we will identify 3-5 mutation hot spots. Then based on the hot spots, we will construct a combinatorial mutation library to find the best 3-5 combinations with desired affinity.

This method improves the screening efficiency and increases the probability of obtaining high affinity sequences.

Together with FASEBA screening we can guarantee to increase the antibody affinity to target antigen by 5-10 fold and it can go up to 100 folds. In our past case, we have successfully increased the affinity by 100 fold from 10-10 to 10-12.

Our FASEBA (Fast Screening for Expression, Biophysical-properties and Affinity) is a patented E.Coli based system that selects good affinity, expression level and thermostable candidates.


FASEBA – Fast Screening Expression Biophysical-Properties and Affinity

FASEBA technology is used to select the best protein binders from a large number of protein candidates in a high throughput fashion, without actually purifying these proteins. FASEBA selection is based on the expression level, biophysical properties, Binding affinity, cell binding, and functional activity of protein candidates.

Phage Display Library Based Affinity Maturation

GenScript ProBio also provides the traditional phage display based affinity maturation.
We can guarantee affinity improvement to nM Level by phage display library based methods.

Phage Display Library

Service Highlights

  • 30+ affinity maturation projects delivered
  • Phage display library and PML library based methods meeting the highest delivery standards in the industry
  • Guarantee affinity improvement to nM Level by phage display
  • Guarantee 5-10 fold affinity improvement by PML library. In our past case, affinity can be increased by 100 fold from 10-10 to 10-12.
  • As fast as 8 weeks to deliver antibody sequences with desired affinity

Deluxe Package-PML library based affinity maturation SC1979

Description Deliverable Timeline
PML library construction & FASEBA screening
  • Sequences of a panel of top 5 antibodies
  • 0.2 mg each of 5 selected antibodies, purity > 85%.
8-13 weeks
Construction of combinatorial library & screening
Production and characterization of affinity-matured antibody (Up to three)

Economical Package-Phage display library based affinity maturation SC2222

Description Deliverable Timeline
Parental IgG binding confirmation
  • 3-5 sequences
  • Full-length purified antibodies (30ml/ piece)
  • experimental report
8-12 weeks
Phage display library construction, panning and screening
Affinity matured IgG production
Affinity measurement by SPR

Please contact us mentioning "Discovery Biology", our customer service representatives are available 24 hours a day, Monday through Friday to assist you.